Nasdaq:CUE
Cue Biopharma, Inc.
A clinical-stage biopharma firm advancing oncology and inflammation therapies with a strong pipeline but no commercial sales yet.
Key Metrics
Investment Thesis
Bull Case
The stock offers exposure to high-potential cancer and inflammation therapies with a potential for substantial value creation upon successful clinical trials and regulatory approval. The company maintains a healthy liquidity position with over $22 million in cash, providing sufficient runway to advance its pipeline without immediate distress. Strategic partnerships could unlock significant non-dilutive capital and commercial distribution capabilities, enhancing the value of the underlying intellectual property.
Bear Case
Investors face substantial downside risk given the consistent net losses exceeding $40 million annually with no current commercial revenue stream to support operations. The company has a significant accumulated deficit of nearly $352 million, indicating a long history of burning cash without achieving profitability. Future stock price volatility is expected to remain high due to the binary nature of clinical trial outcomes and potential dilution from future fundraising rounds.
About Cue Biopharma, Inc.
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel treatments for cancer and inflammatory diseases. Operating primarily within the United States market, the firm leverages its proprietary platform to advance multiple programs through preclinical and clinical development stages. The company currently generates revenue from licensing agreements and collaborations while investing heavily in research and development to reach key clinical milestones.
Analysis
Management Discussion
Cue Biopharma reported a net loss of $40.7 million in 2024, with operating expenses totaling $50.8 million driven largely by research and development costs of $36.3 million. Despite the negative cash flow from operations, the company successfully raised capital through share issuances, resulting in a net increase in cash reserves to approximately $22.6 million. The reduction in loss year-over-year suggests improved cost management or milestone recognitions, though the company remains dependent on external funding to sustain its development pipeline.
Industry Overview
The biotechnology sector is characterized by rapid innovation in oncology and immunology, where companies compete through proprietary drug discovery platforms and strategic alliances. Success in this market requires significant capital investment to navigate the lengthy regulatory approval process and expensive clinical trial requirements. Consolidation among smaller firms often occurs as only those with differentiated science or strong partnership pipelines achieve commercial viability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.2M | $5.5M | $9.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $1.2M | $5.5M | $9.3M |
| Operating Expenses | $54.5M | $57.6M | $50.8M |
| Operating Income | $-53.2M | $-52.1M | $-41.5M |
| R&D | $38.6M | $40.8M | $36.3M |
| G&A | $16.2M | $16.7M | $14.6M |
| Stock-Based Comp | $9.5M | $8.2M | $6.8M |
| D&A | $922.2K | $556.0K | $397.0K |
| Depreciation | $830.6K | $545.0K | $385.0K |
| Other OpEx | $-276.6K | $157.0K | $-93.0K |
| Non-Operating Income | $214.4K | $0 | $0 |
| Interest Expense | — | $130.0K | $100.0K |
| Pre-Tax Income | $-53.0M | $-52.1M | $-41.5M |
| Income Tax | $0 | $-1.4M | $-826.0K |
| Continuing Ops | $-53.0M | $-50.7M | $-40.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-53.0M | $-50.7M | $-40.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-53.0M | $-50.7M | $-40.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $77.2M | $51.5M | $25.1M |
| Cash & Equivalents | $51.6M | $48.5M | $22.5M |
| Accounts Receivable | $57.3K | $1.7M | $945.0K |
| Prepaid Expenses | $841.2K | $1.2M | $805.0K |
| Other Current Assets | $24.7M | $0 | $929.0K |
| Long-Term Assets | $14.1M | $10.1M | $7.1M |
| PP&E (Net) | $1.5M | $795.0K | $471.0K |
| Operating Leases | $9.2M | $6.3M | $4.4M |
| Other LT Assets | $3.4M | $3.0M | $2.2M |
| Total Assets | $91.3M | $61.5M | $32.2M |
| Current Liabilities | $11.5M | $17.1M | $13.7M |
| Accounts Payable | $2.7M | $3.5M | $2.8M |
| Current Debt | $2.0M | $4.0M | — |
| Current Leases | $3.3M | $3.4M | $3.5M |
| Other Current Liab | $-37.0K | $2.1M | $4.4M |
| Long-Term Liabilities | $14.1M | $7.4M | $1.0M |
| Long-Term Debt | $8.0M | $4.2M | $0 |
| LT Operating Leases | $6.0M | $3.2M | $1.0M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $25.6M | $24.4M | $14.7M |
| Shareholders' Equity | $65.7M | $37.1M | $17.5M |
| Retained Earnings | $-250.5M | $-301.2M | $-341.9M |
| AOCI | $-95.9K | $0 | — |
| Total L&E | $91.3M | $61.5M | $32.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-53.0M | $-50.7M | $-40.7M |
| Non-Cash Adjustments | $15.3M | $7.4M | $7.2M |
| Working Capital Changes | $-4.1M | $3.4M | $-2.8M |
| Cash from Operations | $-41.8M | $-40.0M | $-36.3M |
| Capital Expenditures | $170.7K | $0 | $66.0K |
| Cash from Investing | $-24.6M | $25.0M | $32.0K |
| Share Buybacks | $199.9K | $0 | — |
| Cash from Financing | $53.7M | $11.9M | $10.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-12.8M | $-3.1M | $-26.1M |
| Beginning Cash | $64.5M | $51.8M | $48.7M |
| Ending Cash | $51.8M | $48.7M | $22.6M |
Frequently Asked Questions
How does Cue Biopharma, Inc. make money?
The company's financial profile indicates a pre-revenue model reliant on strategic partnerships, evidenced by significant cash flow from financing activities offsetting operating losses. Revenue is likely derived from upfront payments or milestones associated with license agreements for its drug candidates rather than direct product sales. Current operations are heavily weighted toward R&D expenses and general administrative costs typical of early-stage biotechnology development.
What are the main risks for CUE?
Significant dilution risk due to recurring need for equity financing to cover substantial net losses and negative operating cash flows. Clinical trial failure risk inherent to all pre-commercial biotechnology companies developing novel cancer and inflammatory treatments. Regulatory uncertainty surrounding the approval process for new drug candidates by the FDA or other global health authorities. Dependence on key personnel and intellectual property protection as the primary assets in a highly competitive therapeutic landscape.
What is CUE's competitive advantage?
Access to a proprietary molecular platform that enables the generation of novel therapeutic agents for hard-to-treat indications. Strong financial runway provided by substantial cash reserves relative to current operating burn rates, allowing flexibility in program prioritization. Potential for high-value licensing deals with large pharmaceutical partners who provide funding and development expertise in exchange for future royalties.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.